Cargando…

High Tumor Mitochondrial DNA Content Correlates With an Improved Patient's Outcome in WHO Grade III Meningioma

Background: Studies have shown mitochondrial genome content (mtDNA content) varies in many malignancies. However, its distribution and prognostic values in high-grade meningioma remain largely unknown. In this retrospective study, we sought to assess a putative correlation between the mtDNA content...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hua, Lingyang, Juratli, Tareq A., Zhu, Hongda, Deng, Jiaojiao, Wang, Daijun, Sun, Shuchen, Xie, Qing, Wakimoto, Hiroaki, Gong, Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530740/ https://www.ncbi.nlm.nih.gov/pubmed/33072573 http://dx.doi.org/10.3389/fonc.2020.542294

Ejemplares similares

Prognostic Model That Predicts Benefits of Adjuvant Radiotherapy in Patients With High Grade Meningioma
por: Wang, Daijun, et al.
Publicado: (2020)

TERT Alterations Predict Tumor Progression in De Novo High-Grade Meningiomas Following Adjuvant Radiotherapy
por: Deng, Jiaojiao, et al.
Publicado: (2021)

m(6)A Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes
por: Chen, Jiawei, et al.
Publicado: (2021)

Application of MRI-Based Radiomics in Preoperative Prediction of NF2 Alteration in Intracranial Meningiomas
por: Sun, Shuchen, et al.
Publicado: (2022)

The Diagnostic Value Of Using (18)F-Fluorodeoxyglucose Positron Emission Tomography To Differentiate Between Low- And High-Grade Meningioma
por: Hua, Lingyang, et al.
Publicado: (2019)

Radiation Treatment for WHO Grade II and III Meningiomas
por: Walcott, Brian P., et al.
Publicado: (2013)

The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations
por: Deng, Jiaojiao, et al.
Publicado: (2020)

LncRNA-IMAT1 Promotes Invasion of Meningiomas by Suppressing KLF4/hsa-miR22-3p/Snai1 Pathway
por: Ding, Yaodong, et al.
Publicado: (2022)

The efficacy of preoperative MRI features in the diagnosis of meningioma WHO grade and brain invasion
por: Jiang, Jun, et al.
Publicado: (2023)

Analysis of Prognostic Factors of World Health Organization Grade Ⅲ Meningiomas
por: Tian, Weidong, et al.
Publicado: (2020)

A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4
por: Williams, Erik A., et al.
Publicado: (2023)

Development and Validation of Prognostic Nomogram in Patients With WHO Grade III Meningioma: A Retrospective Cohort Study Based on SEER Database
por: Jia, Zetian, et al.
Publicado: (2021)

Mitotic and Proliferative Indices in WHO Grade III Meningioma
por: Daniela Maier, Andrea, et al.
Publicado: (2020)

Synthesizing Molecular and Immune Characteristics to Move Beyond WHO Grade in Meningiomas: A Focused Review
por: Kannapadi, Nivedha V., et al.
Publicado: (2022)

Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic
por: Williams, Erik A., et al.
Publicado: (2020)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas
por: González-Tablas, María, et al.
Publicado: (2021)

The Discrepancy Between Standard Histologic WHO Grading of Meningioma and Molecular Profile: A Single Institution Series
por: Roehrkasse, Amanda M., et al.
Publicado: (2022)

Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma
por: Zhu, Hongda, et al.
Publicado: (2019)

TERT promoter mutations in primary and secondary WHO grade III meningioma
por: Maier, Andrea Daniela, et al.
Publicado: (2020)

Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas
por: Juratli, Tareq A., et al.
Publicado: (2017)

Recurrence/Regrowth in Grade I Meningioma: How to Predict?
por: de Carvalho, Gervásio Teles Cardoso, et al.
Publicado: (2020)

Specific gene expression signatures of low grade meningiomas
por: Tsitsikov, Erdyni N., et al.
Publicado: (2023)

WHO Grade I Meningioma Recurrence: Identifying High Risk Patients Using Histopathological Features and the MIB-1 Index
por: Haddad, Alexander F., et al.
Publicado: (2020)

A Clinical Prognostic Model Based on Preoperative Hematological and Clinical Parameters Predicts the Progression of Primary WHO Grade II Meningioma
por: Gao, Peng, et al.
Publicado: (2021)

Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma
por: Kawamura, Yoichiro, et al.
Publicado: (2022)

Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord
por: Hua, Lingyang, et al.
Publicado: (2022)

A Clinical Semantic and Radiomics Nomogram for Predicting Brain Invasion in WHO Grade II Meningioma Based on Tumor and Tumor-to-Brain Interface Features
por: Li, Ning, et al.
Publicado: (2021)

Intracranial Grade II Meningioma Oligometastatic to the Cervical Spine
por: Natarajan, Jyotsna M, et al.
Publicado: (2021)

Gene Expression Signatures Identify Biologically Homogenous Subgroups of Grade 2 Meningiomas
por: Zador, Zsolt, et al.
Publicado: (2020)

CD133-Positive Cells Might Be Responsible for Efficient Proliferation of Human Meningioma Cells
por: Tang, Hailiang, et al.
Publicado: (2012)

MNG-03 PD-L1 EXPRESSION, PATIENT PROGNOSIS AND INITIAL WHO GRADE IN GRADE II/III MENINGIOMA
por: Kamamoto, Dai, et al.
Publicado: (2019)

Predicting the grade of meningiomas by clinical–radiological features: A comparison of precontrast and postcontrast MRI
por: Yao, Yuan, et al.
Publicado: (2022)

Association of perioperative adverse events with subsequent therapy and overall survival in patients with WHO grade III and IV gliomas
por: Weber, Lorenz, et al.
Publicado: (2022)

Histological transformation in recurrent WHO grade I meningiomas
por: Corniola, Marco V., et al.
Publicado: (2020)

Clinicopathologic Characteristics of Grade 2/3 Meningiomas: A Perspective on the Role of Next-Generation Sequencing
por: Kim, Junhyung, et al.
Publicado: (2022)

EMMPRIN expression positively correlates with WHO grades of astrocytomas and meningiomas
por: Tsai, Wen-Chiuan, et al.
Publicado: (2013)

Nrf2 Expressions Correlate with WHO Grades in Gliomas and Meningiomas
por: Tsai, Wen-Chiuan, et al.
Publicado: (2016)

Analysis of Gene Expression Profiling in Meningioma: Deregulated Signaling Pathways Associated with Meningioma and EGFL6 Overexpression in Benign Meningioma Tissue and Serum
por: Wang, Xuanchun, et al.
Publicado: (2012)

Emerging Medical Treatments for Meningioma in the Molecular Era
por: Nigim, Fares, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_98dd02g32e7hvkt1qtjlk0pci9